Mangoceuticals, Common Company Insiders
| MGRX Stock | 2.47 0.34 12.10% |
Mangoceuticals, Common employs about 3 people. The company is managed by 4 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.75 employees per reported executive. Break down of Mangoceuticals, Common's management performance can provide insight into the company performance.
Mangoceuticals, |
Mangoceuticals, Common Management Team Effectiveness
The company has return on total asset (ROA) of (0.6272) % which means that it has lost $0.6272 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1831) %, meaning that it created substantial loss on money invested by shareholders. Mangoceuticals, Common's management efficiency ratios could be used to measure how well Mangoceuticals, Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -59.98 in 2025. Return On Capital Employed is likely to drop to -0.6 in 2025. At this time, Mangoceuticals, Common's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 741.4 K in 2025, whereas Total Current Assets are likely to drop slightly above 71.8 K in 2025.Common Stock Shares Outstanding is likely to drop to about 1.9 M in 2025. Net Loss is likely to rise to about (1.7 M) in 2025
Mangoceuticals, Common Workforce Comparison
Mangoceuticals, Common Stock is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 5,867. Mangoceuticals, Common adds roughly 3.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Mangoceuticals, Common Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mangoceuticals, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mangoceuticals, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mangoceuticals, Common insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Isaac Antonios over two weeks ago Insider Trading | ||
D'alessio Lorraine Pamela over a month ago Acquisition by Dalessio Lorraine Pamela of 100000 shares of Mangoceuticals, Common subject to Rule 16b-3 | ||
Isaac Antonios over two months ago Insider Trading | ||
Eugene Johnston over three months ago Acquisition by Eugene Johnston of 25000 shares of Mangoceuticals, Common subject to Rule 16b-3 | ||
Jacob Cohen over six months ago Disposition of 8000000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3 | ||
Jacob Cohen over six months ago Disposition of 800000 shares by Jacob Cohen of Mangoceuticals, Common subject to Rule 16b-3 | ||
Hamilton Alex P. over six months ago Disposition of 108426 shares by Hamilton Alex P. of Mangoceuticals Common at 0.32 subject to Rule 16b-3 | ||
Hamilton Alex P. over six months ago Disposition of 16574 shares by Hamilton Alex P. of Mangoceuticals Common at 0.31 subject to Rule 16b-3 |
Mangoceuticals, Common Notable Stakeholders
A Mangoceuticals, Common stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mangoceuticals, Common often face trade-offs trying to please all of them. Mangoceuticals, Common's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mangoceuticals, Common's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jacob Cohen | CEO CoFounder | Profile | |
| Jonathan Arango | Secretary President | Profile | |
| Eugene Johnston | Chief Officer | Profile | |
| Amanda Hammer | Chief Officer | Profile |
About Mangoceuticals, Common Management Performance
The success or failure of an entity such as Mangoceuticals, Common often depends on how effective the management is. Mangoceuticals, Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mangoceuticals, management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mangoceuticals, management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (63.14) | (59.98) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.57) | (0.59) | |
| Return On Equity | (0.62) | (0.66) |
Please note, the imprecision that can be found in Mangoceuticals, Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mangoceuticals, Common Stock. Check Mangoceuticals, Common's Beneish M Score to see the likelihood of Mangoceuticals, Common's management manipulating its earnings.
Mangoceuticals, Common Workforce Analysis
Traditionally, organizations such as Mangoceuticals, Common use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mangoceuticals, Common within its industry.Mangoceuticals, Common Manpower Efficiency
Return on Mangoceuticals, Common Manpower
| Revenue Per Employee | 157.8K | |
| Revenue Per Executive | 118.3K | |
| Net Loss Per Employee | 2.9M | |
| Net Loss Per Executive | 2.2M |
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.